4 Jun 2017 | Medical New Bulletin
The small molecule, anandamide, is an endocannabinoid synthesized in the gut. Anandamide plays a key role in gut health and immune response.
3 Jun 2017 | Task and Purpose
The waiting room at the Scottsdale Research Institute in Arizona could be any doctor’s office, except for the faint smell of marijuana.
1 Jun 2017 | ABC News
An active compound in cannabis plants, once isolated, could be used to treat symptoms of schizophrenia according to findings of a new study.
30 May 2017 | Forbes
Since the legalization movement began hitting full stride, new research discoveries about marijuana’s potential health benefits have been surfacing with regularity.
26 May 2017 | Now Toronto
“Once legalization comes in, where are people supposed to smoke? In the park, or are they expected to go to an alleyway? Vapour lounges are a much more civilized way of dealing with a problem," says Abi Roach, founder of Hot Box Café.
25 May 2017 | Greenhouse Canada
Although cannabis had been used for many centuries for treatment of seizure disorders, medical use became prohibited in the 20th century. However, with the loosening of laws regarding medical marijuana, research and clinical use of marijuana-derived substances are increasing.
24 May 2017 | CNN
Cannabidiol, which is found in marijuana plants, reduced the number of convulsive seizures in children with a severe and often fatal epilepsy disorder, according to research published Wednesday in the New England Journal of Medicine.
23 May 2017 | ABC News
As the Tasmanian Government prepares to spend almost $4 million on a controlled access scheme for medicinal cannabis, some people who already use the drug have raised concerns about the scheme's effectiveness.
22 May 2017 | Blue Mountains Gazette
Katoomba GP, Teresa Towpik, is singing the praises of medicinal cannabis.
19 May 2017 | Proactive Investors Australia
AusCann Group Holdings (ASX:AC8) has raised $12 million through the placement of 24 million shares priced at $0.50 to institutional and high net worth investors. Significantly, the placement price is more than double the price of the company’s ASX debut in February of $0.20.